Expression Level and Significance of GP73，TGF-β1 and Smad2 in Hepatocellular Carcinoma Tissues

doi:10.3969/j.issn.1007-9572.2016.26.013

Abstract

Abstract: Objective　To investigate the relationship between Golgi protein 73（GP73），TGF-β/Smads signaling pathway and hepatocellular carcinoma.Methods　80 cases of paraffin-embedded samples of hepatocellular carcinoma tissues and para-carcinoma tissues collected by Pathology Department of the First Affiliated Hospital of Xinjiang Medical University were selected from January 2010 to December 2014.And clinical data of these patients were consulted from the Medical Records Room of our hospital，including gender，age，hepatitis B surface antigen（HBsAg），alpha fetoprotein（AFP）level，with or without liver cirrhosis，with or without portal vein tumor thrombus，differentiation degree，TNM staging，with or without vascular invasion.Immunohistochemistry EnVision system was adopted to detect positive expression and IOD of GP73 and TGF-β1，Smad2 in hepatocellular carcinoma tissues and para-carcinoma tissues.Results　GP73，claybank particles，were located in cytoplasm.The positive expression rate of GP73 in hepatocellular carcinoma tissues was 73.8%（59/80），higher than 5.0%（4/80）（χ2=76.50，P<0.05） of para-carcinoma tissues.TGF-β1，Smad2 mainly expressing in cytoplasm，occasionally in karyon，were claybank dense granule.TGF-β1 positive expression rate in hepatocellular carcinoma tissues was 81.2%（65/80），higher than 6.2%（5/80）（χ2=65.67，P<0.05）of para-carcinoma tissues.Smad2 positive expression rate in hepatocellular carcinoma tissues was 66.2%（53/80），higher than 10.0%（8/80）（χ2=47.62，P<0.05）of para-carcinoma tissues.Spearman relevant analysis results showed that GP73 correlated positively with TGF-β1，Smad2（rs=0.841，0.405，P<0.05）.The comparison of the expression levels of GP73，Smad2 in patients with different gender were not statistically significant（P>0.05），the comparison of the expression levels of TGF-β1 in patients with different gender was statistically significant（P<0.05）；the comparison of the expression levels of GP73，TGF-β1 and Smad2 in patients with different age，HBsAg，AFP，with or without liver cirrhosis，with or without portal vein tumor thrombus were not statistically significant（P>0.05）；the comparison of the expression levels of GP73，TGF-β1 and Smad2 in patients with different differentiation degree，TNM staging，with or without vascular invasion were all statistically significant（P<0.05）.Conclusion　GP73，mainly expressing positively in hepatocellular carcinoma tissues，may be involved in the occurrence and development of hepatocellular carcinoma through the regulation of TGF-β/Smads signaling pathway.

Key words: Carcinoma, hepatocellular, Transforming growth factor beta1, Smad2 protein, Golgi protein 73

摘要： 目的　探讨高尔基体蛋白73（GP73）及转化生长因子β（TGF-β）/Smads信号通路与肝细胞癌（肝癌）的关系。方法　选取2010年1月—2014年12月新疆医科大学第一附属医院病理科收集的80例肝癌患者的肝癌组织及癌旁组织蜡块标本，并从本院病案室调阅患者的临床病历资料，包括性别、年龄、乙型肝炎表面抗原（HBsAg）、血清甲胎蛋白（AFP）水平、有无肝硬化、有无门静脉癌栓、分化程度、TNM分期、有无血管侵犯。采用免疫组织化学EnVision二步法检测肝癌组织和癌旁组织GP73、TGF-β1和Smad2的阳性表达情况和积分光密度（IOD）。结果　GP73定位于胞质，呈棕黄色颗粒。肝癌组织GP73阳性表达率为73.8%（59/80），高于癌旁组织的5.0%（4/80）（χ2=76.50，P<0.05）。TGF-β1和Smad2主要表达于胞质，偶见于胞核，为棕黄色深染颗粒。肝癌组织TGF-β1阳性表达率为81.2%（65/80），高于癌旁组织的6.2%（5/80）（χ2=65.67，P<0.05）；肝癌组织Smad2阳性表达率为66.2%（53/80），高于癌旁组织的10.0%（8/80）（χ2=47.62，P<0.05）。Spearman相关分析结果显示，GP73与TGF-β1、Smad2呈正相关（rs=0.841、0.405，P<0.05）。不同性别患者肝癌组织GP73、Smad2表达水平比较，差异均无统计学意义（P>0.05），TGF-β1表达水平比较，差异有统计学意义（P<0.05）；不同年龄、HBsAg、AFP、有无肝硬化及门静脉癌栓患者肝癌组织GP73、TGF-β1和Smad2表达水平比较，差异均无统计学意义（P>0.05）；不同分化程度、TNM分期、有无血管侵犯患者肝癌组织GP73、TGF-β1和Smad2表达水平比较，差异均有统计学意义（P<0.05）。结论　GP73在肝癌组织中多呈阳性表达，其可能通过调控TGF-β/Smads信号通路参与肝癌的发生与发展。

关键词: 癌, 肝细胞, 转化生长因子β1, Smad2蛋白质, 高尔基体蛋白73

HUANG Feng-ling, YANG Ying, ZHANG Rui-li, MAO Rui, LIU Pan, SUN Yi, ZHANG Hua, BAO Yong-xing. Expression Level and Significance of GP73，TGF-β1 and Smad2 in Hepatocellular Carcinoma Tissues[J]. Chinese General Practice, 2016, 19(26): 3191-3195.

黄风玲, 杨颖, 张瑞丽, 毛睿, 刘攀, 孙毅, 张华, 包永星. 肝细胞癌组织中高尔基体蛋白73和转化生长因子β1及Smad2的表达水平及其意义[J]. 中国全科医学, 2016, 19(26): 3191-3195.

References

［1］Global Burden of Disease Cancer Collaboration，FITZMAURICE C，DICKER D，et al.The global burden of cancer 2013［J］.JAMA Oncol，2015，1（4）：505-527. ［2］WU T T，BOITNOTT J.Dysplastic nodules：a new term for premalignant hepatic nodular lesions［J］.Radiology，1996，201（1）：21-22. ［3］KLADNEY R D，BULLA G A，GUO L，et al.GP73，a noval Golgi-localized protein upregulated by viral infection［J］.Gene，2000，249（1/2）：53-65. ［4］KLADNEY R D，CUI X，BULLA G A，et al.Expression of GP73，a resident Golgi membrane protein，in viral and nonviral liver disease［J］.Hepatology，2002，35（6）：1431-1440. ［5］MAITRA A，THULUVATH P J.GP73 and liver disease：a（golgi）complex enigma［J］.Am J Gastroenterol，2004，99（6）：1096-1098. ［6］毛一雷，杨华瑜，徐海峰，等.新的肝癌血清标记物GP73在肝癌诊断中的初步研究［J］.中华医学杂志，2008，88（14）：948-951. MAO Y L，YANG H Y，XU H F，et al.Significance of Golgiglycoprotein 73，a new tumor marker in diagnosis of hepatocellular carcinoma：a primary study［J］.National Medical Journal of China，2008，88（14）：948-951. ［7］杨颖，木尼热·马合苏提，包永江，等.GP73和AFP单项与联合诊断原发性肝癌的价值［J］.中华检验医学杂志，2012，35（11）：1034-1037. ［8］杨颖，肖蕾，毛睿，等.高尔基体蛋白73的表达特征及其对肝癌与肝硬化的鉴别诊断价值［J］.中华肝脏病杂志， 2012，20（12）：920-924. YANG Y，XIAO L，MAO R，et al.Expression profiles and differential diagnostic value of serum Golgi protein-73 in patients with liver cirrhosis and primary hepatic carcinoma［J］.Chinese Journal of Hepatology，2012，20（12）：920-924. ［9］包永星，杨颖，赵化荣，等.高尔基体蛋白73对早期肝癌的诊断价值及临床意义［J］.中华肿瘤杂志，2013，35（7）：505-508. BAO Y X，YANG Y，ZHAO H R，et al.Clinical significance and diagnostic value of Golgi-protein 73 in patients with early-stage primary hepatocellular carcinoma［J］.Chinese Journal of Oncology，2013，35（7）：505-508. ［10］CHAFFER C L，WEINBERG R A.A perspective on cancer cell metastasis［J］.Science，2011，331（6024）：1559-1564. ［11］BAO Y X，CAO Q，YANG Y，et al.Expression and prognostic significance of golgiglycoprotein73（GP73）with epithelial-mesenchymal transition（EMT）related molecules in hepatocellular carcinoma（HCC）［J］.Diagn Pathol，2013，8：197. ［12］毛睿，杨颖，曹茜，等.高尔基体糖蛋白73在肝细胞肝癌组织中的表达及意义［J］.世界华人消化杂志，2014，22（32）：4996-5000. MAO R，YANG Y，CAO Q，et al.Significance of expression of Golgiglycoprotein 73 in hepatocellular carcinoma［J］.World Chinese Journal of Digestology，2014，22（32）：4996-5000. ［13］ZHANG Y L，ZHANG Y C，HAN W，et al.Effect of GP73 silencing on proliferation and apoptosis in hepatocellular cancer［J］.World J Gastroenterol，2014，20（32）：11287-11296. ［14］WENDT M K，TIAN M，SCHIEMANN W P，et al.Deconstructing the mechanisms and consequences of TGF-β induced EMT during cancer progression［J］.Cell Tissue Res，2012，347（1）：85-101. ［15］GREGORY P A，BRACKEN C P，SMITH E，et al.Anautocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition［J］.Mol Biol Cell，2011，22（10）：1686-1698. ［16］DERYNCK R，ZHANG Y E.Smad-dependent and Smad-independent pathways in TGF-beta family signaling［J］.Nature，2003，425（6958）：577-584. ［17］ZHANG Y E.Non-smad pathways in TGF-beta signaling［J］.Cell Res，2009，19（1）：128-139.

[1]	YANG Haifei, SUN Wu, WU Cheng, REN Wei, LI Rutian. Analysis of Predictors for Immune-related Adverse Events and the Correlation with Efficacy in Progressive Esophageal Squamous Cell Carcinoma [J]. Chinese General Practice, 2026, 29(06): 710-717.
[2]	ZHANG Shujing, SUN Lixin, CAO Yuqing. Comparative Study on the Clinicopathological Features and Prognostic between HPV-related and Non-HPV-related Cervical Adenocarcinoma [J]. Chinese General Practice, 2025, 28(14): 1758-1764.
[3]	YUAN Xiaorui, TAN Yanlin, FU Chun. Construction of the Predictive Model for Lymph Node Metastasis in Patients with Epithelial Ovarian Cancer: Based on ¹⁸F-FDG PET/CT Radiomics Technology [J]. Chinese General Practice, 2025, 28(12): 1465-1472.
[4]	ZHANG Yushuang, WU Zhongbing, HUANG Ming, JIA Lei, GAO Shuang, ZHAO Weipeng, LI Jing. Study on Metabolic Characteristics in Esophageal Squamous Cell Carcinoma Patients with TCM Differentiation of Deficiency of Fluid and Blood Based on Non Target Metabolomics [J]. Chinese General Practice, 2025, 28(12): 1513-1519.
[5]	LOU Xianzhe, MIAO Tongguo, ZHANG Shiya, MA Dong, NAN Yuemin. The Impact of the Monocyte-to-High-Density Lipoprotein Cholesterol Ratio on the Prognosis of Patients with Non-Viral, Non-Alcoholic Hepatocellular Carcinoma: a Retrospective Cohort Study [J]. Chinese General Practice, 2025, 28(09): 1092-1099.
[6]	MA Xiaoxuan, WANG Rongqi. Research Progress in Metabolomics for HCC Diagnosis and Treatment [J]. Chinese General Practice, 2025, 28(08): 1017-1022.
[7]	SONG Fenfen, LI Shengmian. Real-World Study of Camrelizumab-based Regimen for Locally Advanced and Metastatic Esophageal Cancer [J]. Chinese General Practice, 2025, 28(07): 844-852.
[8]	ZHANG Jin, SUN Di, WANG Hao, SHI Cong, ZHAO Yihan, PAN Yijin, MU Zhuanzhuan, DING Zhiguo, LIN Yansong. Factors Influencing Biochemical Progression in Distant Metastatic Papillary Thyroid Carcinoma [J]. Chinese General Practice, 2024, 27(36): 4546-4553.
[9]	YANG Anyin, LIU Hongli, CHEN Miaoyang, ZHENG Yufeng, XU Zhiyuan, YANG Yongfeng. Mechanism and in Vitro Experiment of Wogonin in Treatment of Hepatocellular Carcinoma Based on Network Pharmacology [J]. Chinese General Practice, 2024, 27(32): 4040-4049.
[10]	CHEN Chao, CHEN Tianxiang, LIU Qianwei, ZHANG Zhi, WANG Huanhuan, WU Pingping, GAO Lei, YU Zhaoxiang. Analysis and Identification of Hub Genes in Hepatocellular Carcinoma Based on Weighted Gene Co-expression Network and Cancer Genome Atlas Clinical Data [J]. Chinese General Practice, 2024, 27(32): 4050-4059.
[11]	MAIERHABA· Maimaitiaili, ZHANG Kainan, ZHAO Hui, YAKUFU· Tuoheti, YE Jianwei, LYU Guodong. Investigating Serum PARP2 as a Potential Diagnostic Biomarker for Hepatocellular Carcinoma [J]. Chinese General Practice, 2024, 27(32): 4060-4065.
[12]	HU Lingxi, LI Mei, FU Yiwei, LU Lixia, MA Xiaoxuan, WANG Rongqi, NAN Yuemin. The Value of Serum VEGF in Evaluating the Clinical Efficacy of TACE Alone or Combined with Target Immunotherapy in Advanced Hepatocellular Carcinoma [J]. Chinese General Practice, 2024, 27(32): 4033-4039.
[13]	LIN Xinrong, JIA Lei, LI Lifeng, HUANG Ming, WU Zhongbing, LI Jing. Study on the Inhibition of Esophageal Carcinoma Development in Mice by Salvia Chinensia Benth Induced Ferroptosis [J]. Chinese General Practice, 2024, 27(30): 3784-3789.
[14]	LI Zhiyong, LI Guohua, HUANG Pengfei, ZHANG Yunjing, LOU Xianzhe, ZHAO Junjian. Association of Peripheral Blood Mononuclear Cell to HDL Cholesterol Ratio with Papillary Thyroid Carcinoma in Different Genders [J]. Chinese General Practice, 2024, 27(25): 3159-3163.
[15]	ZHANG Yun, CAI Xinyi, DING Jingnuo, LU Shengwei, CHEN Cuiying, WU Tingting, ZHANG Junli, ZHAO Weifeng. Study on the Value of Oligosaccharide Chain and Alpha-fetoprotein for Risk Screening and Diagnosis of Hepatitis B Virus-related Hepatocellular Carcinoma [J]. Chinese General Practice, 2024, 27(15): 1855-1860.